Pre-biologic,hisT-spotwas positive andhischestradiograph was abnormal.He hadnochestsymptoms. ACT-chestdemonstrated multiplebilateral ground-glass opacities. Pulmonary function tests (PFTs) revealed an elevatedKCO (130%predicted). A lungbiopsy revealed alveolar haemorrhage, alveolitis, capillaritis and a mixed inflammatory infiltrate consistent with APS. Infection (including tuberculosis), malignancy and granulomatous disease were all excluded. The patient was subsequently treated with high-dose corticosteroids and rituximab. His other treatment for APS remained unchanged. He was also treated for latent tuberculosis with isoniazid. Since this treatment regimen the patient has had no further thrombotic episodes. Moreover, repeat CT-chest and PFTs have both shown significant improvements. Discussion: Primary APS is an autoimmune thrombophilic disorder characterised by recurrent arterial and venous thromboembolism, and obstetric morbidity. Deep vein thrombosis and stroke are the most common venous and arterial thrombotic manifestations respectively. Treatment includes the use of anticoagulation such as warfarin. Refractory APS is associated with recurrent thrombotic episodes despite anticoagulation therapy. Our patient developed recurrent cerebral thrombosis despite warfarin and clopidogrel. This continued to occur even after increasing the INR-target. Furthermore, prior to and during each thrombotic episode, our patient's INR was always within the desired range. We also added secondary treatments for APS including atorvastatin and hydroxychloroquine and these also failed to prevent further cerebrovascular disease. We did not feel changing warfarin to low molecular weight heparin alone was sufficient to prevent further thromboses given the history of optimal INRs. We therefore opted to also add rituximab given its role in preventing further production of B-cell driven autoantibodies via CD20 binding. In addition, our patient had significant APSdriven pulmonary abnormalities which required addressing. Pulmonary embolism and pulmonary hypertension are the most common respiratory pathologies of APS. Rarely APS can also cause pulmonary artery thrombosis and fibrosing alveolitis. Moreover and particular to our patient, it can cause alveolar haemorrhage, alveolitis and pulmonary capillaritis. This occurs via neutrophilic infiltration of the alveolar septum and pulmonary capillary wall, and microthrombi which results in inflammation. Necrosis and loss of capillary integrity then causes disruption of the alveolar-capillary basement membrane resulting in haemorrhage. Remarkably despite the evident APS-driven lung disease in our patient, he was asymptomatic from achestperspective. Our patient has responded positively to rituximab with improvement in PFTs and CT-chest appearance. Moreover he has had no further thrombotic events. We aim to repeat brain imaging and recheck APS antibody titres to observe the effect of rituximab. Key learning points: Excluding pulmonary embolism and pulmonary hypertension, pulmonary disease is an under-recognised manifestation of APS. Rarer lung sequelae include pulmonary capillaritis, alveolitis and alveolar haemorrhage which our patient exhibited. These pathologies require a combination of investigations to diagnose including imaging, PFTs and histopathological biopsy. Most cases of APS respond to first-line treatment with anticoagulation such as warfarin provided INR targets are consistently achieved. Our patient continued to have recurrent thrombotic cerebrovascular events despite anticoagulation, antiplatelet therapy and other treatments. This case raises awareness of a complex refractory APS case which necessitated the introduction of biologic therapy in rituximab. Rituximab is already well-recognised in the treatment of catastrophic APS. We intend by this case to raise awareness of the effectiveness of rituximab in noncatastrophic APS, and its value in treating inflammatory APS-driven lung pathology. We await results for the effect of rituximab on APS-antibodies and whether this has anyimpact on prevention of disease progression. This case also highlights the importance of a multidisciplinary approach in managing complex cases. We worked alongside other specialities including neurology,strokemedicine,haematology andrespiratorymedicine to achieve optimalpatient care.
Introduction: Vasculitis can be a primary or secondary process. Underlying secondary causes include infection, malignancy and other autoimmune conditions. This case describes a patient with findings consistent with ANCA-associated vasculitis. As part of investigations, she was identified as having a PET-avid lung lesion for which she is currently undergoing further investigation via the respiratory team.From a rheumatological perspective she is receiving treatment for her vasculitis, however at present it is unclear whether this is a secondary paraneoplastic phenomenon. This case explores the nature of her presentation and the relationship of primary versus secondary paraneoplastic vasculitis. Case description: A 75-year-old lady presented to hospital with a 6week history of fatigue, pyrexia and myalgia. During this period she additionally noted numbness/neuropathic pains affecting her feet. She had a background of COPD/asthma diagnosed 10 years previously. She had additionally undergone polypectomy for nasal-polyps and had underwent right mastectomy in 1990 for breast cancer. She was noted to have raised inflammatory markers (CRP 256) and eosinophilia. She was deemed to have an infective exacerbation of COPD/ asthma although at the time she had limited respiratory symptoms and CXR was reported normal. She was initiated on a 5-day course of prednisolone 40mg and antibiotics. Her symptoms appeared to respond to treatment, as did her CRP and eosinophilia, and shewas discharged. Unfortunately she re-presented with similar symptoms within a few days. Further investigation and blood tests demonstrated cANCA antibodies with PR3 of 128 IU. Urine PCR was mildly raised at 30mg/mmol. She was reviewed by the rheumatology team, and likely diagnosis of ANCA-associated vasculitis was made. It was noted however that while her serology was suggestiveof granulomatosiswith polyangiitis (GPA), her clinical picture of eosinophilia, COPD/asthma and nasal-polyps was more consistent with eosinophilic granulomatosis with polyangiitis (EGPA). She was re-initiatedon prednisolone 40mg and demonstrated clinical response. As part of work-up, CT-CAP was arranged. This reported a spiculated lesion of the right-upper lung lobe with appearances concerning for malignancy. Subsequent PET-CT confirmed this be PET-avid, with additional suspicious nodules. She was additionally arranged for nerve-conduction studies regarding her feet symptoms, with findings being consistent with mononeuritis multiplex. From a rheumatological perspective, she has been initiated on azathioprine and prednisolone is gradually being reduced. She has ongoing follow up with respiratory regarding her lung lesion, with initial biopsy being inconclusive. Further attempt at gaining histology is currently awaited. Discussion: From a rheumatological perspective, aspects of this case support a diagnosis of ANCA-associated vasculitis. Presence of cANCA with PR3 antibodies are typically associated with GPA, although her eosinophilia, asthma and previous history of nasal polyps would be more consistent with EGPA. The features of mononeuritis multiplex on nerve conduction studies would also support an underlying diagnosis of vasculitis. Although there is a documented relationship between malignancy and vasculitis, this appears to be relatively rare with a 5-8% association. Haematological malignancies such as lymphoma and MDS have a greater association in comparison to solid tumours. Typical manifestation of paraneoplastic vasculitis is that of cutaneous involvement, particularly of leukocytoclastic vasculitis. Reports suggest improvement of secondaryvasculitis ontreatment of the underlying condition. With regards to the association of ANCA-vasculitis and solid tumour malignancy, cases appear to be less well-described. The majority of case studies exploring the link between these conditions are primarily in the context of secondary malignancy occurring after immunosuppressive therapy (such as cyclophosphamide) for vasculitis. Review of literature outside of this context, especially in regards of specifically lung malignancy is limited -so a consistent established link may be less apparent. Of the limited studies, interestingly there have been reports of patients with biopsy proven lung malignancy and raised MPO/PR3, with levels normalising following treatment of the underlying lesion. Asdescribed inthiscase,ourpatientcurrentlyawaits furtherinvestigation regarding her lung lesion and subsequent review of its definitive intervention. Should investigations confirm malignancy and this be treated, then it would be interesting to see whether there is clinical resolution of her systemic vasculitis secondary tothis. Key learning points: This case demonstrates the presence of 2 conditions of ANCA-associated vasculitis and possible lung malignancy which were both diagnosed during the same admission. Literature suggests possible association between vasculitis and malignancy in a general sense, however specific description of ANCA-vasculitis and lung malignancy hasbeen rarely described. At present, this patient's vasculitis is being managed whilst definitive intervention is being arranged for her underlying lung lesion. Continued follow up from both the rheumatologists and respiratory team is ongoing and response of her condition will be assessed pending intervention of her underlying lunglesion. Conflicts of interest: The authors have declared no conflicts of interest.
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